Cognex Corporation 10-K Summary: Fiscal Year Ended December 31, 1998
Business Context and Reporting Period
This filing covers the fiscal year ended December 31, 1998. Cognex Corporation designs, develops, and markets machine vision systems used to automate manufacturing processes. The company serves two primary customer types: Original Equipment Manufacturers (OEMs) and end users across industries such as semiconductor, electronics, automotive, and consumer products. Approximately 63% of revenue in 1998 was derived from international customers.
Key Financial Metrics
Specific revenue, net income, cash flow, and debt figures are not provided in the text of this 10-K filing; they are incorporated by reference from the Annual Report to Stockholders (Exhibit 13). However, the following metrics are explicitly stated:
- Research, Development, and Engineering (R, D & E) Expenses: $24,662,000 (20% of revenue) for 1998.
- Backlog: $17,216,000 as of December 31, 1998.
- Market Capitalization: Aggregate market value of voting stock held by non-affiliates was $1,008,663,000 as of February 28, 1999.
- Shares Outstanding: 40,346,520 shares of common stock as of February 28, 1999.
- Allowance for Doubtful Accounts: Ended at $2,583,000.
- Reserve for Inventory Obsolescence: Ended at $2,860,000.
Material Changes vs. Prior Period
- Backlog Decline: Backlog decreased significantly to $17,216,000 in 1998 from $32,618,000 in 1997.
- R&D Investment Increase: R&D expenses rose to $24.7 million (20% of revenue) in 1998, compared to $22.5 million (14% of revenue) in 1997 and $19.4 million (16% of revenue) in 1996.
- Customer Concentration: Fuji America Corporation accounted for 14% of revenue in 1998, down from 18% in 1997.
- Product Launches: Introduced the MVS-8000 product family (C++ programmable), PatInspect software, and SmartView Modular Camera Network in 1998.
Outlook, Risks, and Management Commentary
Strategy: Cognex aims to expand its position as a leading worldwide supplier by focusing on high value-added products and expanding its direct sales infrastructure for end users, while maintaining its strong OEM position. The company intends to retain all earnings to finance development and does not intend to pay cash dividends in the foreseeable future.
Legal Contingency: The company is involved in litigation with the Lemelson Medical, Educational, & Research foundation regarding patent infringement claims. Cognex filed a complaint in September 1998 seeking a declaration that Lemelson's machine vision patents are invalid. The outcome is uncertain and could materially affect financial results.
Market Risks: The company faces exposure to foreign currency exchange rates (primarily Japanese yen) and interest rate changes. As of February 1, 1999, a hypothetical strengthening of the dollar against the yen indicated a potential gain of $976,000 on forward contracts. Interest rate sensitivity analysis suggests a 50 basis point move would not materially impact the fair value of the investment portfolio.
Investor Verification Checklist
- Verify total revenue, net income, and operating cash flow figures in the Annual Report to Stockholders (Exhibit 13), as they are not listed in this text.
- Review the backlog trend given the 47% year-over-year decline to $17.2 million.
- Monitor the status of the Lemelson patent litigation and potential indemnification claims from customers.
- Assess the impact of the increased R&D spend (20% of revenue) on future profitability and product competitiveness.
- Confirm the concentration risk regarding international sales (63%) and the single largest customer, Fuji America Corporation (14%).